• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application
o Oncology – Market size and forecast 2019-2024
o Autoimmune disorders – Market size and forecast 2019-2024
o Infectious diseases – Market size and forecast 2019-2024
o Other applications – Market size and forecast 2019-2024
o Market opportunity by Application
• Market Segmentation by Type
o Segmentation by type of monoclonal antibodies
• Customer Landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Competitive Scenario
o Vendor Landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AbbVie Inc.
o AstraZeneca Plc
o Bristol-Myers Squibb Co.
o F. Hoffmann-La Roche Ltd.
o GlaxoSmithKline Plc
o Johnson & Johnson
o Merck & Co. Inc.
o Novartis AG
o Pfizer Inc.
o Sanofi
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Key Finding 9
• 9: Parent market
• 10: Market characteristics
• 11: Offerings of vendors included in the market definition
• 12: Market segments
• 13: Global – Market size and forecast 2019 – 2024 ($ billion)
• 14: Global market: Year-over-year growth 2019 – 2024 (%)
• 15: Five forces analysis 2019 & 2024
• 16: Bargaining power of buyers
• 17: Bargaining power of suppliers
• 18: Threat of new entrants
• 19: Threat of substitutes
• 20: Threat of rivalry
• 21: Market condition – Five forces 2019
• 22: Application – Market share 2019-2024 (%)
• 23: Comparison by Application
• 24: Oncology – Market size and forecast 2019-2024 ($ billion)
• 25: Oncology – Year-over-year growth 2019-2024 (%)
• 26: Autoimmune disorders – Market size and forecast 2019-2024 ($ billion)
• 27: Autoimmune disorders – Year-over-year growth 2019-2024 (%)
• 28: Infectious diseases – Market size and forecast 2019-2024 ($ billion)
• 29: Infectious diseases – Year-over-year growth 2019-2024 (%)
• 30: Other applications – Market size and forecast 2019-2024 ($ billion)
• 31: Other applications – Year-over-year growth 2019-2024 (%)
• 32: Market opportunity by Application
• 33: Type – Market share 2019-2024 (%)
• 34: Comparison by Type
• 35: Market opportunity by Type
• 36: Customer landscape
• 37: Market share by geography 2019-2024 (%)
• 38: Geographic comparison
• 39: North America – Market size and forecast 2019-2024 ($ billion)
• 40: North America – Year-over-year growth 2019-2024 (%)
• 41: Europe – Market size and forecast 2019-2024 ($ billion)
• 42: Europe – Year-over-year growth 2019-2024 (%)
• 43: Asia – Market size and forecast 2019-2024 ($ billion)
• 44: Asia – Year-over-year growth 2019-2024 (%)
• 45: ROW – Market size and forecast 2019-2024 ($ billion)
• 46: ROW – Year-over-year growth 2019-2024 (%)
• 47: Key leading countries
• 48: Market opportunity by geography ($ billion)
• 49: Impact of drivers and challenges
• 50: Vendor landscape
• 51: Landscape disruption
• 52: Industry risks
• 53: Vendors covered
• 54: Market positioning of vendors
• 55: AbbVie Inc. – Overview
• 56: AbbVie Inc. – Business segments
• 57: AbbVie Inc. – Key offerings
• 58: AbbVie Inc. – Key customers
• 59: AbbVie Inc. – Segment focus
• 60: AstraZeneca Plc – Overview
• 61: AstraZeneca Plc – Product and service
• 62: AstraZeneca Plc – Key offerings
• 63: AstraZeneca Plc – Key customers
• 64: AstraZeneca Plc – Segment focus
• 65: Bristol-Myers Squibb Co. – Overview
• 66: Bristol-Myers Squibb Co. – Product and service
• 67: Bristol-Myers Squibb Co. – Key offerings
• 68: Bristol-Myers Squibb Co. – Key customers
• 69: Bristol-Myers Squibb Co. – Segment focus
• 70: F. Hoffmann-La Roche Ltd. – Overview
• 71: F. Hoffmann-La Roche Ltd. – Business segments
• 72: F. Hoffmann-La Roche Ltd. – Key offerings
• 73: F. Hoffmann-La Roche Ltd. – Key customers
• 74: F. Hoffmann-La Roche Ltd. – Segment focus
• 75: GlaxoSmithKline Plc – Overview
• 76: GlaxoSmithKline Plc – Business segments
• 77: GlaxoSmithKline Plc – Key offerings
• 78: GlaxoSmithKline Plc – Key customers
• 79: GlaxoSmithKline Plc – Segment focus
• 80: Johnson & Johnson – Overview
• 81: Johnson & Johnson – Business segments
• 82: Johnson & Johnson – Key offerings
• 83: Johnson & Johnson – Key customers
• 84: Johnson & Johnson – Segment focus
• 85: Merck & Co. Inc. – Overview
• 86: Merck & Co. Inc. – Business segments
• 87: Merck & Co. Inc. – Key offerings
• 88: Merck & Co. Inc. – Key customers
• 89: Merck & Co. Inc. – Segment focus
• 90: Novartis AG – Overview
• 91: Novartis AG – Business segments
• 92: Novartis AG – Key offerings
• 93: Novartis AG – Key customers
• 94: Novartis AG – Segment focus
• 95: Pfizer Inc. – Overview
• 96: Pfizer Inc. – Business segments
• 97: Pfizer Inc. – Key offerings
• 98: Pfizer Inc. – Key customers
• 99: Pfizer Inc. – Segment focus
• 100: Sanofi – Overview
• 101: Sanofi – Business segments
• 102: Sanofi – Key offerings
• 103: Sanofi – Key customers
• 104: Sanofi – Segment focus
• 105: Currency conversion rates for US$
• 106: Research Methodology
• 107: Validation techniques employed for market sizing
• 108: Information sources
• 109: List of abbreviations
【掲載企業】
AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi
【免責事項】
https://www.marketreport.jp/reports-disclaimer